Abstract
Background Antibody responses to MF59-adjuvanted (MF59Flu) and high-dose (HDFlu) influenza vaccines have been well-characterized in older adults, yet corresponding cellular response data remain limited.
Methods Blood samples were collected from 106 MF59Flu recipients and 112 HDFlu recipients before vaccination (Day 0), and on Days 1, 8, and 28 post-vaccination. Antibody responses were assessed on Days 0, 8, and 28 using a hemagglutination inhibition (HAI) assay. Eight pro-inflammatory cytokines and chemokines, including IFN-α2a, IFN-γ, IP-10, MCP-1, MIP-1α, IL-1β, IL-6, IL-8, were quantified from PBMCs collected on Days 0 and 1 following stimulation with live influenza A/H3N2 virus using a multiplex assay. Associations between cytokine/chemokine levels and HAI titers were examined, along with the effect of sex, age, body mass index (BMI), and cytomegalovirus infection status.
Results Vaccine type (MF59Flu or HDFlu), sex, BMI and cytomegalovirus infection did not significantly impact cytokine and chemokine levels. However, age was positively correlated with IL-8 level on Day 1 (r = 0.24, p = 0.0003) as well as the change in IL-8 levels from Day 1 to Day 0 (r = 0.16, p = 0.021). Notably, the change in IL-8 levels was negatively associated with peak antibody responses at Day 28 (r = −0.15, p = 0.026).
Conclusion Our findings underscore IL-8 as a potential link between aging and impaired antibody responses to influenza vaccination in older adults, suggesting that IL-8 inhibition could be a promising molecular intervention to improve immunogenicity and efficacy of influenza vaccines in this high-risk population.
Competing Interest Statement
Dr. Poland is the chair of a safety evaluation committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland provides consultative advice to AiZtech; Emergent Biosolutions; GlaxoSmithKline; Invivyd; Janssen Global Services, LLC; Merck & Co. Inc.; Moderna; Novavax; and Syneos Health. Dr. Poland holds patents related to vaccinia, influenza, and measles peptide vaccines. Dr. Poland is an adviser to the White House and World Health Organization on COVID-19 vaccines and monkeypox, respectively. Drs. Poland, Kennedy, and Ovsyannikova have received grant funding and royalties from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. Drs. Poland, Kennedy, and Ovsyannikova have a pending patent related to COVID-19 peptide-based vaccines. Dr. Kennedy also offers consultative advice on vaccine development to Merck & Co. and Sanofi Pasteur. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. Other co-authors declare no competing interests.
Funding Statement
This research was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health with grant number R01AI132348, the Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP) with contract number 75N93019C00052 (CIVIC). The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Mayo Clinic Institutional Review Board (IRB# 17-010601) and conducted in accordance with the Declaration of Helsinki. All study participants provided written informed consent prior to enrollment in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
All data included in this study are presented as figures and tables and available from the corresponding author upon reasonable request.
